Skip to main content
Gideon Blumenthal, MD, Oncology, Bethesda, MD, Holy Cross Hospital

GideonMichaelBlumenthalMD

Oncology Bethesda, MD

Hematologic Oncology, Thoracic Cancer

Thoracic Malignancies and Head and Neck Cancer, FDA

Dr. Blumenthal is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Blumenthal's full profile

Already have an account?

  • Office

    8901 Wisconsin Ave
    National Navy Medical Center Bldg. 8, Rm. 4152
    Bethesda, MD 20889
    Phone+1 301-435-5868
  • Is this information wrong?

Education & Training

  • National Institutes of Health Clinical Center
    National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 2006 - 2009
  • University of Maryland
    University of MarylandResidency, Internal Medicine, 2003 - 2006
  • University of Maryland School of Medicine
    University of Maryland School of MedicineClass of 2003

Certifications & Licensure

  • MD State Medical License
    MD State Medical License 2006 - 2024
  • NC State Medical License
    NC State Medical License 2011 - 2012

Awards, Honors, & Recognition

  • Commissioner’s Special Citation FDA, 2014
  • Recognition Award FDA CDER Group, 2011

Publications & Presentations

PubMed

Journal Articles

  • Analysis of Time to Treatment Discontinuation of Targeted Therapy, Immunotherapy, and Chemotherapy in Clinical Trials of Patients with Non-Small Cell Lung Cancer  
    G R Oxnard, G M Blumenthal, P G Kluetz, R Pazdur, Annals of Oncology
  • FDA Innovation Brings New Therapies to Lung Cancer Patients  
    Pazdur R, Blumenthal G, FDA Voice Blog, 5/5/2014
  • Inside the Black Box: Molecularly Targeted Therapy for Lung Cancer  
    Blumenthal G, Mansfield E, The ASCO Post, 1/15/2014
  • Join now to see all

Abstracts/Posters

  • Second Cancers in Adults with Acute Promyelocytic Leukemia (APL) Treated with or without Arsenic Trioxide (ATO): A SEER-Medicare Analysis
    Gideon Blumenthal, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Meta-analysis Results from the Collaborative Trials in Neoadjuvant Breast Cancer (CTNeoBC).
    Cortazar C, Zhang L, Untch M, Mehta K, Constantino J, Wolmark N, Bonnefoi H, Cameron D, Gianni L, Valagussa P, Zujewski J, Justice R, Loibl S, Wickerham L, Bogaerts J,..., General Session I, San Antonio Breast Cancer Symposium, 12/5/2012
  • Sunitinib for the treatment of pancreatic neuroendocrine tumor (pNET)
    Blumenthal G.M., Oncologic Drug Advisory Committee, Silver Spring, MD, 4/12/2011
  • Join now to see all

Lectures

  • Histologic-Agnostic Trials: Challenges and Opportunities—A Regulatory Perspective 
    ASCO Annual Meeting 2019 - Chicago, IL - 6/3/2019
  • Analysis of Immune-Related Adverse Reactions in Patients with Classical Hodgkin Lymphoma (cHL) on Programmed Death-1 (PD-1) Inhibitor Therapy 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • When don’t we need a phase III trial? 
    Chicago, IL - 5/1/2014
  • Join now to see all

Press Mentions

  • How to Succeed in Modernizing Clinical Trials
    How to Succeed in Modernizing Clinical TrialsJanuary 10th, 2017
  • Public Workshop - Next Generation Sequencing-Based Oncology Panels, February 25, 2016
    Public Workshop - Next Generation Sequencing-Based Oncology Panels, February 25, 2016February 25th, 2016
  • Special Issue Looks at What’s Ahead in Precision Medicine
    Special Issue Looks at What’s Ahead in Precision MedicineAugust 16th, 2015
  • Join now to see all

Professional Memberships

Hospital Affiliations